Physician profile
Jay Geoghagan
NPI 1407840101
$6,159.43
in general payments reported to CMS, 2019-2025
29 companies · $823 in 2025
The $823 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,108 · 2020: $580 · 2021: $876 · 2022: $953 · 2023: $930 · 2024: $890 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,623 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,622.69 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,419.61 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $789.73 | 2019-2024 | Xarelto |
| Pfizer INC. | $719.48 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $580.78 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $541.77 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $296.92 | 2019-2022 | |
| Novo Nordisk INC | $240.23 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $221.07 | 2019-2024 | Farxiga |
| Alnylam Pharmaceuticals INC. | $182.55 | 2022-2025 | Amvuttra |
| Merck Sharp & Dohme LLC | $169.21 | 2021-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $157.27 | 2019-2020 | |
| Abbott Laboratories | $137.68 | 2021-2023 | Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit |
| Bayer Healthcare Pharmaceuticals INC. | $93.24 | 2024-2025 | |
| Abiomed | $81.76 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $69.66 | 2023-2024 | Inpefa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $63.51 | 2020 | |
| Philips North America LLC | $60.32 | 2020-2022 | |
| Baxter Healthcare | $51.17 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| Actelion Pharmaceuticals US, INC. | $45.67 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.17 | 2019-2024 | Lifevest |
| Lundbeck LLC | $31.81 | 2019 | |
| Braemar Manufacturing, LLC | $31.69 | 2019 | |
| Astellas Pharma US INC | $29.45 | 2019-2020 | |
| Bardy Diagnostics, INC. | $23.00 | 2020-2022 | |
| Bridgebio Pharma, INC. | $19.84 | 2025 | Attruby |
| Irhythm Technologies, INC. | $17.96 | 2024 | Zio At Patch |
| Kiniksa Pharmaceuticals International, Plc | $14.31 | 2024 | Arcalyst |
| Lilly USA, LLC | $13.86 | 2025 | Zepbound |
| Esperion Therapeutics, INC. | $12.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Geoghagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.